Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01625234
Title Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

Advanced Solid Tumor

Therapies

Ensartinib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope National Med Ctr Duarte California 91010 United States Details
UCSD Moores Cancer Center La Jolla California 92093 United States Details
University of Southern California Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Stanford University Stanford California 94305 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Walter Reed National Military Medical Center Bethesda Maryland 20889 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
New York University Langone Medical Center New York New York 10016 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
Tennessee Oncology, PLLC Nashville Tennessee 37203 United States Details
Vanderbilt University Nashville Tennessee 37240 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
University of Wisconsin Carbone Cancer Ctr Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field